Exonhit files patent on blood-based Alzheimer's test

By Elaine Rigoli

Tampa, Fla., May 19 - ExonHit Therapeutics has filed a patent with the French Intellectual Property Institute that covers a panel of genes that could enable the differential diagnosis of Alzheimer's patients from blood.

The use of these genes will allow the identification of patients suffering from Alzheimer's disease from a population of elderly patients with no signs of cognitive disorders, the company said in a news release.

By using its gene-profiling technology, ExonHit said it has been able to identify a molecular fingerprint in the immune system that results from changes brought about by the neuro-degeneration that takes place in Alzheimer's patients.

This approach has enabled ExonHit to discover the underlying alternative splicing alterations in the modified cells of the immune system that are present in patients with the disease, the release said.

ExonHit, a drug and diagnostic discovery company, has headquarters in Paris.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.